

Press Release

FOR IMMEDIATE RELEASE

Contact: Michael DeVeau

Head of Investor Relations and Communications & Divisional CFO, Scent

212.708.7164

Michael.DeVeau@iff.com

IFF Reports First Quarter 2019 Results

Achieved double-digit sales growth; Reconfirms full year guidance

NEW YORK, N.Y., (May 6, 2019) – International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF) reported financial results for the first quarter ended March 31, 2019.

First Quarter 2019 Consolidated Summary:

| | Reported (GAAP) | |
|---------|---------------------|--------|
| Sales | Operating Profit | EPS |
| \$1.3 B | \$164 M | \$0.96 |

| Adjusted (Non-GAAP)¹ | | | | | | | |
|-------------------------|---------------------|--------|------------------------|--|--|--|--|
| Sales | Operating Profit | EPS | EPS Ex Amortization | | | | |
| \$1.3 B | \$205 M | \$1.24 | \$1.57 | | | | |

Management Commentary

"Our first quarter results were in line with our expectations and reflect strong progress in the company's transformation following the Frutarom acquisition," said Andreas Fibig, IFF Chairman and CEO. "In the first quarter of 2019, we achieved solid sales growth across all three of our divisions and maintained strong profitability levels despite the continued higher raw material cost environment. On a consolidated basis, the combination of our legacy business performance, plus the addition of Frutarom, yielded double-digit sales and adjusted operating profit growth.

"We are executing well against our integration roadmap. For those businesses where we have aligned our go-to-market approach with IFF – North America Taste and IBR – growth is very strong, increasing double-digits. We are also seeing great progress from procurement synergies and are well underway in terms of our manufacturing optimization plan. For 2019, we are confident that we will achieve our \$30 to \$35 million cost savings goal as our current run-rate savings are already in excess of this target.

Consolidated

¹ Schedules at the end of this release contain reconciliations of reported GAAP to non-GAAP metrics.

"Looking forward, we expect sales growth and profitability to improve in the second half of the year. We remain focused on executing our strategy and integrating successfully, and by doing so, we have reiterated our full year financial guidance."

First Quarter 2019 Consolidated Financial Results

- Reported net sales for the first quarter totaled \$1.3 billion, an increase of 39% from \$931.0 million in 2018, including the contribution of sales related to Frutarom. On a combined basis, currency neutral sales improved 3%, excluding the contribution of acquisitions and divested businesses, with growth across all segments.
- Reported earnings per share (EPS) for the first quarter was \$0.96 per diluted share versus \$1.63 per diluted share reported in 2018. Excluding those items that affect comparability, adjusted EPS ex amortization was \$1.57 per diluted share in 2019 versus \$1.78 in the year-ago period as adjusted operating profit growth was more than offset by higher interest expense and shares outstanding, both related to the Frutarom acquisition.

First Quarter 2019 Segment Summary: Growth vs. Prior Year

 Reported (GAAP)

 Sales
 Segment Profit

 Scent
 1%
 (8)%

 Taste
 (1)%
 (3)%

 Frutarom

| Currency Neutral (Non-GAAP) | | | | | |
|-----------------------------|------|--|--|--|--|
| Sales Segment Profit | | | | | |
| 4% | (3)% | | | | |
| 2% | (1)% | | | | |
| _ | - | | | | |

Scent Business Unit

- On a reported basis, sales increased 1%, or \$6.4 million, to \$488.4 million. Currency neutral sales improved 4%, with growth in nearly all regions and categories. Performance was strongest in Fine Fragrances, increasing double-digits, led by strong new win performance. Consumer Fragrances grew mid-single digits, with the strongest growth in Home Care and Fabric Care. Fragrance Ingredients was challenged as price increases related to higher raw material costs were more than offset by volume declines.
- Scent segment profit decreased 8% on a reported and 3% on a currency neutral basis as
 the benefits from cost and productivity initiatives were more than offset by unfavorable price
 to input costs.

Taste Business Unit

On a reported basis, sales decreased 1%, or \$4.4 million, to \$444.6 million. Currency
neutral sales improved 2%, with growth in three of four regions. Performance in the quarter
was driven by mid-single digit growth in Greater Asia, where India and Indonesia grew

- double-digits, and EAME, led by strong growth in Africa and the Middle East as well as Western Europe. In North America, year-over-year improvements continue to be led by TastePoint. Latin America declined primarily due to volumes with multinational customers.
- Taste segment profit decreased 3% on a reported basis and 1% on a currency neutral basis, as volume growth and the benefits from productivity initiatives were more than offset by unfavorable price to raw material costs and mix.

Frutarom Business Unit

- On a reported basis, sales were \$364.4 million. On a standalone basis, currency neutral sales grew 3%, excluding the contribution of acquisitions and divested businesses.
 Performance was driven by strong growth in Taste, led by double-digit gains in North America, and solid increases in Savory Solutions, which more than offset declines in F&F ingredients and Natural Colors.
- Segment profit contributed \$29 million in the first quarter; \$68 million excluding amortization. Margin performance continued to be driven by disciplined cost management.

The Company reconfirms its 2019 guidance as follows:

| | Guidance |
|----------------------------------|-----------------|
| Sales | \$5.2B - \$5.3B |
| Adjusted EPS (1) | \$4.90 - \$5.10 |
| Adjusted EPS ex amortization (1) | \$6.30 - \$6.50 |

¹ See Use of Non-GAAP Financial Measures

A copy of the Company's Quarterly Report on Form 10-Q will be available on its website at www.iff.com or at www.sec.gov by May 8, 2019.

Audio Webcast

A live webcast to discuss the Company's first quarter 2019 financial results will be held on May 7, 2019, at 10:00 a.m. ET. The webcast and accompanying slide presentation may be accessed on the Company's IR website at <u>ir.iff.com</u>. For those unable to listen to the live webcast, a recorded version will be made available on the Company's website approximately one hour after the event and will remain available on IFF's website for one year.

Cautionary Statement Under The Private Securities Litigation Reform Act of 1995

This press release includes "forward-looking statements" under the Federal Private Securities Litigation Reform Act of 1995, including statements regarding guidance for full year 2019, expected impact of the acquisition of Frutarom, including cost savings, and our ability to accelerate growth and profitability in 2019. These forward-looking statements are qualified in their entirety by cautionary statements and risk factor disclosures contained in the Company's Securities and Exchange Commission filings, including the Company's Annual Report on Form 10-K filed with the Commission

on February 26, 2019 and subsequent filings with the SEC, including the Company's Quarterly Reports on Form 10-Q. The Company wishes to caution readers that certain important factors may have affected and could in the future affect the Company's actual results and could cause the Company's actual results for subsequent periods to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. With respect to the Company's expectations regarding these statements, such factors include, but are not limited to: (1) risks related to the integration of the Frutarom business, including whether we will realize the benefits anticipated from the acquisition in the expected time frame; (2) unanticipated costs, liabilities, charges or expenses resulting from the Frutarom acquisition, (3) the increase in the Company's leverage resulting from the additional debt incurred to pay a portion of the consideration for Frutarom and its impact on the Company's liquidity and ability to return capital to its shareholders, (4) the Company's ability to successfully market to its expanded and decentralized Taste and Frutarom customer base, (5) the Company's ability to effectively compete in its market and develop and introduce new products that meet customers' needs. (6) the Company's ability to successfully develop innovative and cost-effective products that allow customers to achieve their own profitability expectations, (7) the impact of the disruption in the Company's manufacturing operations, (8) the impact of a disruption in the Company's supply chain, including the inability to obtain ingredients and raw materials from third parties, (9) volatility and increases in the price of raw materials, energy and transportation, (10) the Company's ability to comply with, and the costs associated with compliance with, regulatory requirements and industry standards, including regarding product safety, quality, efficacy and environmental impact, (11) the impact of any failure or interruption of the Company's key information technology systems or a breach of information security, (12) the Company's ability to react in a timely and cost-effective manner to changes in consumer preferences and demands, (13) the Company's ability to establish and manage collaborations, joint ventures or partnership that lead to development or commercialization of products, (14) the Company's ability to benefit from its investments and expansion in emerging markets; (15) the impact of currency fluctuations or devaluations in the principal foreign markets in which it operates: (16) economic, regulatory and political risks associated with the Company's international operations, (17) the impact of global economic uncertainty on demand for consumer products, (18) the inability to retain key personnel; (19) the Company's ability to comply with, and the costs associated with compliance with, U.S. and foreign environmental protection laws, (20) the Company's ability to realize the benefits of its cost and productivity initiatives, (21) the Company's ability to successfully manage its working capital and inventory balances, (22) the impact of the failure to comply with U.S. or foreign anti-corruption and anti-bribery laws and regulations, including the U.S. Foreign Corrupt Practices Act, (23) the Company's ability to protect its intellectual property rights, (24) the impact of the outcome of legal claims, regulatory investigations and litigation, (25) changes in market conditions or governmental regulations relating to our pension and postretirement obligations, (26) the impact of future impairment of our tangible or intangible long-lived assets, (27) the impact of changes in federal, state, local and international tax legislation or policies, including the Tax Cuts and Jobs Act, with respect to transfer pricing and state aid, and adverse results of tax audits, assessments, or disputes, (28) the effect of potential government regulation on certain product development initiatives, and

restrictions or costs that may be imposed on the Company or its operations as a result, and (29) the impact of the United Kingdom's expected departure from the European Union. New risks emerge from time to time and it is not possible for management to predict all such risk factors or to assess the impact of such risks on the Company's business. Accordingly, the Company undertakes no obligation to publicly revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Use of Non-GAAP Financial Measures

We provide in this press release non-GAAP financial measures, including: (i) currency neutral sales, which eliminates the effects that result from translating our international sales in U.S. dollars; (ii) adjusted operating profit and adjusted EPS, which exclude restructuring costs and other significant items of a non-recurring and/or non-operational nature such as gains on sale of assets, operational improvement initiatives, integration related costs, FDA mandated product recall costs, acquisition related costs, Frutarom acquisition related costs, U.S. Tax reform (often referred to as "Items Impacting Comparability); (iii) adjusted EPS ex amortization, which excludes Items Impacting Comparability and the amortization of acquisition related intangible assets; and (iv) currency neutral adjusted EPS ex amortization, which eliminates the effects that result from translating our international sales in U.S. dollars on adjusted EPS ex amortization.

These non-GAAP measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. With respect to the redemption value adjustment to EPS, the Company excluded this adjustment as (i) the amount is not believed to be a measure of earnings and is excluded from the net income attributable to IFF; and (ii) the Company believes that investors may benefit from an understanding of the Company's results without giving effect to this adjustment. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company's results under GAAP and may not be comparable to other companies' calculation of such metrics.

When we provide our expectations for adjusted EPS and adjusted EPS ex amortization for our full year 2019 guidance, the closest corresponding GAAP measure and a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure is not available without unreasonable effort due to length of the forecasted period and potential variability, complexity and low visibility as to items such as future contingencies and other costs that would be excluded from the GAAP measure, and the tax impact of such items, in the relevant future period. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.

In the fourth quarter of fiscal year 2018, we began including Adjusted (Non-GAAP) EPS ex. Amortization as a key non-GAAP financial measure of our business. Full amortization expense of intangible assets acquired in connection with acquisitions will be excluded from Adjusted (Non-GAAP) EPS ex. Amortization calculation. The exclusion of amortization expense allows comparison of operating results that are consistent over time for newly and long-held businesses and with both acquisitive and non-acquisitive peer companies. We believe this calculation will provide a more accurate presentation in this and in future periods in the event of additional acquisitions. Further, this allows the investors to evaluate and understand operating trends excluding the impact on operating income and earnings per diluted share. In addition, the Frutarom acquisition related costs have been separated from costs related to prior acquisitions. The Frutarom acquisition costs represent a significant balance and we believe this amount should be shown separately to provide an accurate presentation of the acquisition related costs. Our GAAP results and GAAP metrics do not change, and this change has no effect on day to day business operations, or how we manage our business. For Frutarom, we present segment profit excluding amortization expense as it allows comparison of operating results that are consistent over time for newly and long-held businesses and with both acquisitive and non-acquisitive peer companies.

We calculated "combined" numbers by combining (i) our results (including Frutarom from January 1, 2019 through March 31, 2019) with (ii) the results of Frutarom prior to its acquisition by us on October 4, 2018, and adjusting for divestitures of Frutarom businesses since October 4, 2018, but do not include any other adjustments that would have been made had we owned Frutarom for such periods prior to October 4, 2018.

Meet IFF

International Flavors & Fragrances Inc. Consolidated Income Statement (Amounts in thousands except per share data) (Unaudited)

| | Three Months Ended March 31, | | | | |
|---|------------------------------|----------|-----------------|---------|-------|
| | 2019 2018 | | | %Change | |
| | | | | | |
| Netsales | \$1 | ,297,402 | \$9 | 930,928 | 39 % |
| Cost of goods sold | | 766,143 | | 525,119 | 46 % |
| Gross profit | | 531,259 | 4 | 405,809 | 31 % |
| Research and development expenses | | 90,596 | | 78,476 | 15 % |
| Selling and administrative expenses | | 213,182 | • | 142,644 | 49 % |
| Amortization of acquisition-related intangibles | | 47,625 | | 9,185 | NMF |
| Restructuring and other charges, net | | 16,174 | | 717 | NMF |
| Gains on sales of fixed assets | | (188) | | (69) | 172 % |
| Operating profit | | 163,870 | | 174,856 | (6)% |
| Interest expense | | 36,572 | | 16,595 | 120 % |
| Other income, net | | (7,278) | | (576) | NMF |
| Income before taxes | | 134,576 | • | 158,837 | (15)% |
| Taxes on income | | 23,362 | | 29,421 | (21)% |
| Net income | \$ | 111,214 | \$ | 129,416 | (14)% |
| Net income attributable to noncontrolling | | | | | |
| interest | | 2,385 | | | NMF |
| Net income attributable to IFF | \$ | 108,829 | \$ ['] | 129,416 | (16)% |
| | | | | | |
| Net income per share - basic ⁽¹⁾ | \$ | 0.97 | \$ | 1.63 | |
| Net income per share - diluted ⁽¹⁾ | \$ | 0.96 | \$ | 1.63 | |
| Average shares outstanding | | | | | |
| Basic | | 111,864 | | 79,018 | |
| Diluted | | 113,389 | | 79,393 | |

⁽¹⁾ For 2019, net income per share reflects adjustments related to the redemption value of certain redeemable noncontrolling interests.

NMF Not meaningful

International Flavors & Fragrances Inc. Condensed Consolidated Balance Sheet (Amounts in thousands) (Unaudited)

| | March 31, 2019 | December 31, 2018 |
|---|-------------------|----------------------|
| Cash, cash equivalents, and restricted cash | \$ 497,129 | \$ 648,522 |
| Receivables | 1,003,965 | 937,765 |
| Inventories | 1,114,488 | 1,078,537 |
| Other current assets | 310,243 | 277,036 |
| Total current assets | 2,925,825 | 2,941,860 |
| Property, plant and equipment, net | 1,294,029 | 1,241,152 |
| Goodwill and other intangibles, net | 8,408,177 | 8,417,710 |
| Other assets | 583,389 | 288,673 |
| Total assets | \$13,211,420 | \$ 12,889,395 |
| | | |
| Short term borrowings | \$ 84,003 | \$ 48,642 |
| Other current liabilities | 1,060,131 | 1,079,669 |
| Total current liabilities | 1,144,134 | 1,128,311 |
| Long-term debt | 4,421,430 | 4,504,417 |
| Non-current liabilities | 1,376,667 | 1,131,487 |
| Redeemable noncontrolling interests | 114,711 | 81,806 |
| Shareholders' equity | 6,154,478 | 6,043,374 |
| Total liabilities and shareholders' equity | \$13,211,420 | \$ 12,889,395 |

International Flavors & Fragrances Inc. Consolidated Statement of Cash Flows (Amounts in thousands) (Unaudited)

| Act income \$111,214 \$129,416 Adjustments to reconcile to net cash provided by (used in) operating activities \$111,214 \$129,416 Depreciation and amortization \$1,755 \$3,3384 Deferred income taxes (12,389) 18,404 Gains on sale of assets (188) (69) Stock-based compensation 7,604 7,629 Pension contributions 0,760 (12,989) Changes in assets and liabilities, net of acquisitions: (55,935) (61,301) Inventories (55,935) (61,301) Inventories (55,935) (61,301) Accounts payable 8,988 (8,483) Accounts for incentive compensation (30,869) (36,583) Other assets (9,978) (26,035) Other liabilities (9,978) (26,035) Net cash provided by (used in) operating activities (33,895) (22 Cash flows from investing activities: (33,895) (22 Cash paid for acquisitions, net of cash received (33,895) (22 Additions to property, plant and equipment | | Three Mon 2019 | ths Ended 2018 |
|--|---|-------------------|-------------------|
| Adjustments to reconcile to net cash provided by (used in) operating activities 81,775 33,848 Depreciation and amortization 81,762 118,404 Gains on sale of assets (12,389) 18,404 Stock-based compensation 7,604 7,620 Pension contributions 12,969 Litigation settlement - (12,969) Changes in assets and liabilities, net of acquisitions: 55,935 (61,301) Inventories (24,719) (30,185) Accounts payable 8,988 (8,435) Accounts payable and accrued expenses (11,321) (18,540) Other assets (99,78) (26,035) Other liabilities (9,978) (26,035) Net cash provided by (used in) operating activities (9,978) (26,035) Net cash provided by (used in) operating activities (33,895) (22 Cash paid for acquisitions, net of cash received (33,895) (22 Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,89 - Maturity of net investment hedge | Cash flows from operating activities: | | |
| Depreciation and amortization 81,775 33,384 Deferred income taxes (12,389) 18,404 Gains on sale of assets (188) (69) Stock-based compensation 7,604 7,620 Pension contributions (3,956) (4,387) Litigation settlement (12,969) Changes in assets and liabilities, net of acquisitions: (55,935) (61,301) Inventories (24,719) (30,185) Accounts payable 8,988 (8,435) Accruals for incentive compensation (36,969) (36,563) Other current payables and accrued expenses (11,321) (18,540) Other isasets (9,078) (26,035) Other liabilities (6,894) (1,715) Net cash provided by (used in) operating activities 3 (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges 2 (2,405) Proceeds from disposal of assets 3,970 293 | Netincome | \$111,214 | \$129,416 |
| Deferred income taxes (12,389) 18,404 Gains on sale of assets (168) (69) Stock-based compensation 7,604 7,620 Pension contributions (3,956) (4,387) Litigation settlement - (12,969) Changes in assets and liabilities, net of acquisitions: (55,935) (61,301) Inventories (55,935) (61,301) Accounts payable (24,719) (30,185) Accounts proxible (36,969) (36,583) Other current payables and accrued expenses (11,321) (18,540) Other assets (9,978) (26,035) Other liabilities (6,894) (17,175) Net cash provided by (used in) operating activities 47,232 (11,391) Cash flows from investing activities: (33,895) (22 Cash paid for acquisitions, net of cash received (33,895) (22 Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investing activities 7 | Adjustments to reconcile to net cash provided by (used in) operating activities | | |
| Gains on sale of assets (188) (69) Stock-based compensation 7,604 7,620 Pension contributions (3,956) (4,387) Litigation settlement - (12,969) Changes in assets and liabilities, net of acquisitions: (55,935) (61,301) Inventories (24,719) (30,185) Accounts payable 8,988 (8,435) Accruals for incentive compensation (36,969) (36,583) Other current payables and accrued expenses (11,321) (18,540) Other liabilities (6,894) (1,715) Net cash provided by (used in) operating activities (6,894) (1,715) Net cash provided by (used in) operating activities (33,895) (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges 2,20 (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities | Depreciation and amortization | 81,775 | 33,384 |
| Stock-based compensation 7,604 7,620 Pension contributions (3,956) (4,387) Litigation settlement - (12,969) Changes in assets and liabilities, net of acquisitions: Trade receivables (55,935) (61,301) Inventories (24,719) (30,185) (8,435) Accounts payable 8,988 (8,435) Accruals for incentive compensation (36,969) (36,583) Other current payables and accrued expenses (11,321) (18,540) Other assets (9,978) (26,035) Other liabilities (9,978) (26,035) Net cash provided by (used in) operating activities T,232 (11,395) Cash paid for acquisitions, net of cash received (33,895) (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges - (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - < | Deferred income taxes | (12,389) | 18,404 |
| Pension contributions (3,956) (4,387) Litigation settlement c (12,969) Changes in assets and liabilities, net of acquisitions: (55,935) (61,301) Inventories (24,719) (30,185) Accounts payable 8,988 (8,455) Accruals for incentive compensation (36,969) (36,583) Other current payables and accrued expenses (11,321) (18,540) Other liabilities (9,978) (26,035) Other liabilities (6,894) (1,715) Net cash provided by (used in) operating activities 347,232 (11,395) Cash flows from investing activities: 2 (22) Cash paid for acquisitions, net of cash received (33,895) (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities (77,779) (54,420) Increase in revolv | Gains on sale of assets | (188) | (69) |
| Litigation settlement - (12,969) Changes in assets and liabilities, net of acquisitions: - (12,969) Trade receivables (55,935) (61,301) Inventories (24,719) (30,185) Accounts payable 8,988 (8,435) Accruals for incentive compensation (36,969) (36,583) Other current payables and accrued expenses (11,321) (18,540) Other assets (9,978) (26,035) Other liabilities (6,894) (17,715) Net cash provided by (used in) operating activities 47,232 (11,395) Cash flows from investing activities: - (22) Cash paid for acquisitions, net of cash received (33,895) (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges - (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities | Stock-based compensation | 7,604 | 7,620 |
| Changes in assets and liabilities, net of acquisitions: Trade receivables (55,935) (61,301) Inventories (24,719) (30,185) Accounts payable 8,988 (8,435) Accruals for incentive compensation (36,969) (36,583) Other current payables and accrued expenses (11,321) (18,540) Other liabilities (9,978) (26,035) Other liabilities (6,894) (17,715) Net cash provided by (used in) operating activities 47,232 (11,395) Cash flows from investing activities: (33,895) (22 Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities (77,779) (54,420) Increase in revolving credit facility and short term borrowings 2,895 53,688 Repayments on debt (36,156) - Proceeds from issuance of stock in connect | Pension contributions | (3,956) | (4,387) |
| Trade receivables (55,935) (61,301) Inventories (24,719) (30,185) Accounts payable 8,988 (8,435) Accruals for incentive compensation (36,969) (36,583) Other current payables and accrued expenses (11,321) (18,540) Other assets (9,978) (26,035) Other liabilities (6,894) (1,715) Net cash provided by (used in) operating activities 47,232 (11,395) Cash flows from investing activities: 3,895 (22) Cash paid for acquisitions, net of cash received (33,895) (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges 2 (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities (77,779) (54,420) Increase in revolving credit facility and short term borrowings 2,895 53,688 Repaymen | Litigation settlement | - | (12,969) |
| Inventories | Changes in assets and liabilities, net of acquisitions: | | |
| Accounts payable 8,988 (8,435) Accruals for incentive compensation (36,969) (36,583) Other current payables and accrued expenses (11,321) (18,540) Other liabilities (9,978) (26,035) Other liabilities (6,894) (17,15) Net cash provided by (used in) operating activities 47,232 (11,395) Cash flows from investing activities Cash paid for acquisitions, net of cash received (33,895) (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges - (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities: (77,779) (54,420) Increase in revolving credit facility and short term borrowings 2,895 53,688 Repayments on debt (36,156) - Proceeds from issuance of stock in connection with stock options 200 - | Trade receivables | (55,935) | (61,301) |
| Accruals for incentive compensation (36,969) (36,583) Other current payables and accrued expenses (11,321) (18,540) Other assets (9,978) (26,035) Other liabilities (6,894) (1,715) Net cash provided by (used in) operating activities 47,232 (11,395) Cash flows from investing activities: \$\text{20}\$ (11,395) Cash paid for acquisitions, net of cash received (33,895) (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges - (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities (90,299) (35,239) Cash flows from financing activities (77,779) (54,420) Increase in revolving credit facility and short term borrowings 2,895 53,688 Repayments on debt (36,156) - Proceeds from issuance of stock in connection with stock options <t< td=""><td>Inventories</td><td>(24,719)</td><td>(30,185)</td></t<> | Inventories | (24,719) | (30,185) |
| Other current payables and accrued expenses (11,321) (18,540) Other assets (9,978) (26,035) Other liabilities (6,894) (1,715) Net cash provided by (used in) operating activities 47,232 (11,395) Cash flows from investing activities: \$\text{20}\$ (33,895) (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges - (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities (90,299) (35,239) Cash flows from financing activities (77,779) (54,420) Increase in revolving credit facility and short term borrowings 2,895 53,688 Repayments on debt (36,156) - Proceeds from issuance of stock in connection with stock options 200 - Employee withholding taxes paid (13,39) (10,617) Net cash used in financing activities | Accounts payable | 8,988 | (8,435) |
| Other assets (9,978) (26,035) Other liabilities (6,894) (1,715) Net cash provided by (used in) operating activities 47,232 (11,395) Cash flows from investing activities: Secondary of the paid for acquisitions, net of cash received (33,895) (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges - (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities (90,299) (35,239) Cash flows from financing activities (77,779) (54,420) Increase in revolving credit facility and short term borrowings 2,895 53,688 Repayments on debt (36,156) - Proceeds from issuance of stock in connection with stock options 200 - Employee withholding taxes paid (13,3) (36,66) - Purchase of treasury stock - (10,617) Net cash used | Accruals for incentive compensation | (36,969) | (36,583) |
| Other assets (9,978) (26,035) Other liabilities (6,894) (1,715) Net cash provided by (used in) operating activities 47,232 (11,395) Cash flows from investing activities: Secondary Cash paid for acquisitions, net of cash received (33,895) (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges 2 (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities (90,299) (35,239) Cash flows from financing activities (77,779) (54,420) Increase in revolving credit facility and short term borrowings 2,895 53,688 Repayments on debt (36,156) - Proceeds from issuance of stock in connection with stock options 200 - Employee withholding taxes paid (13,139) (10,617) Net cash used in financing activities (10,617) (14,615) | Other current payables and accrued expenses | (11,321) | (18,540) |
| Other liabilities (6,894) (1,715) Net cash provided by (used in) operating activities 47,232 (11,395) Cash flows from investing activities: \$ | Other assets | | (26,035) |
| Net cash provided by (used in) operating activities 47,232 (11,395) Cash flows from investing activities: 3,895 (22) Cash paid for acquisitions, net of cash received (33,895) (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges - (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities (90,299) (35,239) Cash flows from financing activities: (77,779) (54,420) Increase in revolving credit facility and short term borrowings 2,895 53,688 Repayments on debt (36,156) - Proceeds from issuance of stock in connection with stock options 200 - Employee withholding taxes paid (1,339) (3,266) Purchase of treasury stock - (10,617) Net cash used in financing activities (112,179) (14,615) Effect of exchange rates changes on cash and cash equiv | Other liabilities | | |
| Cash paid for acquisitions, net of cash received (33,895) (22) Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges - (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities (90,299) (35,239) Cash flows from financing activities: Cash dividends paid to shareholders (77,779) (54,420) Increase in revolving credit facility and short term borrowings 2,895 53,688 Repayments on debt (36,156) - Proceeds from issuance of stock in connection with stock options 200 - Employee withholding taxes paid (1,339) (3,266) Purchase of treasury stock - (10,617) Net cash used in financing activities (112,179) (14,615) Effect of exchange rates changes on cash and cash equivalents 3,853 (1,521) Net change in cash and cash equivalents (151,393) <t< td=""><td>Net cash provided by (used in) operating activities</td><td></td><td></td></t<> | Net cash provided by (used in) operating activities | | |
| Additions to property, plant and equipment (57,609) (33,105) Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges - (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities (90,299) (35,239) Cash flows from financing activities: (77,779) (54,420) Increase in revolving credit facility and short term borrowings 2,895 53,688 Repayments on debt (36,156) - Proceeds from issuance of stock in connection with stock options 200 - Employee withholding taxes paid (1,339) (3,266) Purchase of treasury stock - (10,617) Net cash used in financing activities (112,179) (14,615) Effect of exchange rates changes on cash and cash equivalents 3,853 (1,521) Net change in cash and cash equivalents (151,393) (62,770) | Cash flows from investing activities: | | |
| Proceeds from life insurance contracts 1,890 - Maturity of net investment hedges - (2,405) Proceeds from disposal of assets 3,970 293 Contingent consideration paid (4,655) - Net cash used in investing activities (90,299) (35,239) Cash flows from financing activities: Cash dividends paid to shareholders (77,779) (54,420) Increase in revolving credit facility and short term borrowings 2,895 53,688 Repayments on debt (36,156) - Proceeds from issuance of stock in connection with stock options 200 - Employee withholding taxes paid (1,339) (3,266) Purchase of treasury stock - (10,617) Net cash used in financing activities (112,179) (14,615) Effect of exchange rates changes on cash and cash equivalents 3,853 (1,521) Net change in cash and cash equivalents (151,393) (62,770) | Cash paid for acquisitions, net of cash received | (33,895) | (22) |
| Maturity of net investment hedges Proceeds from disposal of assets Contingent consideration paid Net cash used in investing activities Cash flows from financing activities: Cash dividends paid to shareholders Increase in revolving credit facility and short term borrowings Repayments on debt Proceeds from issuance of stock in connection with stock options Employee withholding taxes paid Purchase of treasury stock Net cash used in financing activities Effect of exchange rates changes on cash and cash equivalents Net change in cash and cash equivalents (2,405) 3,970 293 (3,405) 5 (54,420) (54,420) (54,420) (54,420) (54,420) (54,420) (64,420) (77,779) | Additions to property, plant and equipment | (57,609) | (33,105) |
| Proceeds from disposal of assets3,970293Contingent consideration paid(4,655)-Net cash used in investing activities(90,299)(35,239)Cash flows from financing activities:Cash dividends paid to shareholders(77,779)(54,420)Increase in revolving credit facility and short term borrowings2,89553,688Repayments on debt(36,156)-Proceeds from issuance of stock in connection with stock options200-Employee withholding taxes paid(1,339)(3,266)Purchase of treasury stock-(10,617)Net cash used in financing activities(112,179)(14,615)Effect of exchange rates changes on cash and cash equivalents3,853(1,521)Net change in cash and cash equivalents(151,393)(62,770) | Proceeds from life insurance contracts | 1,890 | - |
| Contingent consideration paid(4,655)-Net cash used in investing activities(90,299)(35,239)Cash flows from financing activities:Cash dividends paid to shareholders(77,779)(54,420)Increase in revolving credit facility and short term borrowings2,89553,688Repayments on debt(36,156)-Proceeds from issuance of stock in connection with stock options200-Employee withholding taxes paid(1,339)(3,266)Purchase of treasury stock-(10,617)Net cash used in financing activities(112,179)(14,615)Effect of exchange rates changes on cash and cash equivalents3,853(1,521)Net change in cash and cash equivalents(151,393)(62,770) | Maturity of net investment hedges | - | (2,405) |
| Net cash used in investing activities(90,299)(35,239)Cash flows from financing activities:(77,779)(54,420)Cash dividends paid to shareholders(77,779)(54,420)Increase in revolving credit facility and short term borrowings2,89553,688Repayments on debt(36,156)-Proceeds from issuance of stock in connection with stock options200-Employee withholding taxes paid(1,339)(3,266)Purchase of treasury stock-(10,617)Net cash used in financing activities(112,179)(14,615)Effect of exchange rates changes on cash and cash equivalents3,853(1,521)Net change in cash and cash equivalents(151,393)(62,770) | Proceeds from disposal of assets | 3,970 | 293 |
| Net cash used in investing activities(90,299)(35,239)Cash flows from financing activities:(77,779)(54,420)Cash dividends paid to shareholders(77,779)(54,420)Increase in revolving credit facility and short term borrowings2,89553,688Repayments on debt(36,156)-Proceeds from issuance of stock in connection with stock options200-Employee withholding taxes paid(1,339)(3,266)Purchase of treasury stock-(10,617)Net cash used in financing activities(112,179)(14,615)Effect of exchange rates changes on cash and cash equivalents3,853(1,521)Net change in cash and cash equivalents(151,393)(62,770) | Contingent consideration paid | (4,655) | - |
| Cash dividends paid to shareholders(77,779)(54,420)Increase in revolving credit facility and short term borrowings2,89553,688Repayments on debt(36,156)-Proceeds from issuance of stock in connection with stock options200-Employee withholding taxes paid(1,339)(3,266)Purchase of treasury stock-(10,617)Net cash used in financing activities(112,179)(14,615)Effect of exchange rates changes on cash and cash equivalents3,853(1,521)Net change in cash and cash equivalents(151,393)(62,770) | Net cash used in investing activities | | (35,239) |
| Increase in revolving credit facility and short term borrowings 2,895 53,688 Repayments on debt (36,156) - Proceeds from issuance of stock in connection with stock options 200 - Employee withholding taxes paid (1,339) (3,266) Purchase of treasury stock - (10,617) Net cash used in financing activities (112,179) (14,615) Effect of exchange rates changes on cash and cash equivalents 3,853 (1,521) Net change in cash and cash equivalents (151,393) (62,770) | Cash flows from financing activities: | | |
| Repayments on debt (36,156) - Proceeds from issuance of stock in connection with stock options 200 - Employee withholding taxes paid (1,339) (3,266) Purchase of treasury stock - (10,617) Net cash used in financing activities (112,179) (14,615) Effect of exchange rates changes on cash and cash equivalents 3,853 (1,521) Net change in cash and cash equivalents (151,393) (62,770) | Cash dividends paid to shareholders | (77,779) | (54,420) |
| Proceeds from issuance of stock in connection with stock options Employee withholding taxes paid Purchase of treasury stock Net cash used in financing activities Effect of exchange rates changes on cash and cash equivalents Net change in cash and cash equivalents 200 - (1,339) (3,266) (10,617) (112,179) (14,615) (151,393) (62,770) | Increase in revolving credit facility and short term borrowings | 2,895 | 53,688 |
| Proceeds from issuance of stock in connection with stock options Employee withholding taxes paid Purchase of treasury stock Net cash used in financing activities Effect of exchange rates changes on cash and cash equivalents Net change in cash and cash equivalents 200 - (1,339) (3,266) (10,617) (112,179) (14,615) (151,393) (62,770) | Repayments on debt | (36,156) | - |
| Purchase of treasury stock-(10,617)Net cash used in financing activities(112,179)(14,615)Effect of exchange rates changes on cash and cash equivalents3,853(1,521)Net change in cash and cash equivalents(151,393)(62,770) | Proceeds from issuance of stock in connection with stock options | | - |
| Purchase of treasury stock-(10,617)Net cash used in financing activities(112,179)(14,615)Effect of exchange rates changes on cash and cash equivalents3,853(1,521)Net change in cash and cash equivalents(151,393)(62,770) | Employee withholding taxes paid | (1,339) | (3,266) |
| Net cash used in financing activities(112,179)(14,615)Effect of exchange rates changes on cash and cash equivalents3,853(1,521)Net change in cash and cash equivalents(151,393)(62,770) | | | |
| Effect of exchange rates changes on cash and cash equivalents3,853(1,521)Net change in cash and cash equivalents(151,393)(62,770) | Net cash used in financing activities | | |
| Net change in cash and cash equivalents (151,393) (62,770) | _ | | |
| | · | | |
| | Cash and cash equivalents at beginning of year | 648,522 | 368,046 |
| Cash and cash equivalents at end of period \$497,129 \$305,276 | Cash and cash equivalents at end of period | | |

International Flavors & Fragrances Inc. Business Unit Performance (Amounts in thousands) (Unaudited)

| | Three Months Ended I | | | March 31, 2018 | |
|--------------------------------------|----------------------|-----------|----|-------------------|--|
| Net Sales | | | | | |
| Taste | \$ | 444,602 | \$ | 449,019 | |
| Scent | | 488,352 | | 481,909 | |
| Frutarom | | 364,448 | | - | |
| Consolidated | | 1,297,402 | | 930,928 | |
| Segment Profit | | | | | |
| Taste | | 108,455 | | 111,564 | |
| Scent | | 85,815 | | 93,277 | |
| Frutarom | | 29,091 | | - | |
| Global Expenses | | (18,673) | | (23,825) | |
| Operational Improvement Initiatives | | (406) | | (1,026) | |
| Acquisition Related Costs | | - | | 514 | |
| Integration Related Costs | | (14,897) | | - | |
| Restructuring and Other Charges, net | | (16,174) | | (717) | |
| Gains on Sale of Assets | | 188 | | 69 | |
| FDA Mandated Product Recall | | - | | (5,000) | |
| Frutarom Acquisition Related Costs | | (9,529) | | - | |
| Operating profit | | 163,870 | | 174,856 | |
| Interest Expense | | (36,572) | | (16,595) | |
| Other income, net | | 7,278 | | 576 | |
| Income before taxes | \$ | 134,576 | \$ | 158,837 | |
| Operating Margin | | | | | |
| Taste | | 24.4 % | | 24.8 % | |
| Scent | | 17.6 % | | 19.4 % | |
| Frutarom | | 8.0 % | | N/A | |
| Consolidated | | 12.6 % | | 18.8 % | |

International Flavors & Fragrances Inc. GAAP to Non-GAAP Reconciliation Foreign Exchange Impact (Unaudited)

Q1 Taste

% Change - Reported (GAAP)

Currency Impact

% Change - Currency Neutral

| Sales | Segment Profit |
|-------|-------------------|
| -1% | -3% |
| 3% | 2% |
| 2% | -1% |

Q1 Scent

% Change - Reported (GAAP)

Currency Impact

% Change - Currency Neutral

| Sales | Segment Profit |
|-------|-------------------|
| 1% | -8% |
| 3% | 5% |
| 4% | -3% |

International Flavors & Fragrances Inc. GAAP to Non-GAAP Reconciliation (Amounts in thousands) (Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Gross Profit

| | First Quarter | | | | |
|---|---------------|---------|----|---------|--|
| | 2019 | | | 2018 | |
| Reported (GAAP) | \$ | 531,259 | \$ | 405,809 | |
| Operational Improvement Initiatives (a) | | 406 | | 453 | |
| Integration Related Costs (c) | | 156 | | - | |
| FDA Mandated Product Recall (e) | | - | | 5,000 | |
| Frutarom Acquisition Related Costs (g) | | 7,850 | | | |
| Adjusted (Non-GAAP) | \$ | 539,671 | \$ | 411,262 | |

Reconciliation of Selling and Administrative Expenses

| | First Quarter | | | | |
|--|---------------|----------|------|---------|--|
| | | 2019 | 2018 | | |
| Reported (GAAP) | \$ | 213,182 | \$ | 142,644 | |
| Acquisition Related Costs (b) | | - | | 514 | |
| Integration Related Costs (c) | | (14,557) | | - | |
| Frutarom Acquisition Related Costs (g) | | (1,679) | | | |
| Adjusted (Non-GAAP) | \$ | 196,946 | \$ | 143,158 | |

Reconciliation of Operating Profit

| | First Quarter | | | | | | | |
|--|---------------|---------|----|---------|--|--|--|--|
| | | 2019 | | 2018 | | | | |
| Reported (GAAP) | \$ | 163,870 | \$ | 174,856 | | | | |
| Operational Improvement Initiatives (a) | | 406 | | 1,026 | | | | |
| Acquisition Related Costs (b) | | - | | (514) | | | | |
| Integration Related Costs (c) | | 14,897 | | - | | | | |
| Restructuring and Other Charges, net (d) | | 16,174 | | 717 | | | | |
| Gains on Sale of Assets | | (188) | | (69) | | | | |
| FDA Mandated Product Recall (e) | | - | | 5,000 | | | | |
| Frutarom Acquisition Related Costs (g) | | 9,529 | | | | | | |
| Adjusted (Non-GAAP) | \$ | 204,688 | \$ | 181,016 | | | | |

International Flavors & Fragrances Inc. GAAP to Non-GAAP Reconciliation (Amounts in thousands) (Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

| | | | | Reconcil | iation o | of Net Income | • | | | | | | | | | |
|--|---------------------|---------|---------------------|----------|--|---------------|-------------|------|---------------------|---------|---------------------|--------|--------------------------------------|---------|-----------------|------|
| | First Quarter | | | | | | | | | | | | | | | |
| | 2019 | | | | | | | 2018 | | | | | | | | |
| | Income before taxes | | Taxes on income (h) | | Net Income Attributable to IFF (i) | | Diluted EPS | | Income before taxes | | Taxes on income (h) | | Net Income Attributable to IFF | | Diluted EPS (j) | |
| Reported (GAAP) | \$ | 134,576 | \$ | 23,362 | \$ | 108,829 | \$ | 0.96 | \$ | 158,837 | \$ | 29,421 | \$ | 129,416 | \$ | 1.63 |
| Operational Improvement Initiatives (a) | | 406 | | 142 | | 264 | | - | | 1,026 | | 294 | | 732 | | 0.01 |
| Acquisition Related Costs (b) | | - | | - | | - | | - | | (514) | | (134) | | (380) | | - |
| Integration Related Costs (c) | | 14,897 | | 3,349 | | 11,548 | | 0.10 | | - | | - | | - | | - |
| Restructuring and Other Charges, net (d) | | 16,174 | | 4,031 | | 12,143 | | 0.11 | | 717 | | 169 | | 548 | | 0.01 |
| Gains on Sale of Assets | | (188) | | (43) | | (145) | | - | | (69) | | (17) | | (52) | | - |
| FDA Mandated Product Recall (e) | | - | | - | | - | | - | | 5,000 | | 1,196 | | 3,804 | | 0.05 |
| U.S. Tax Reform (f) | | - | | - | | - | | - | | - | | (649) | | 649 | | 0.01 |
| Frutarom Acquisition Related Costs (g) | | 9,529 | | 1,530 | | 7,999 | | 0.07 | | | | | | | | - |
| Adjusted (Non-GAAP) | \$ | 175,394 | \$ | 32,371 | \$ | 140,638 | \$ | 1.24 | \$ | 164,997 | \$ | 30,280 | \$ | 134,717 | \$ | 1.69 |

| | | | First Quarter | | |
|---|--------|------------|---------------|-------|------------|
| lumerator | | 2019 | | | 2018 |
| Adjusted (Non-GAAP) Net Income | • | \$ 140,638 | | | \$ 134,717 |
| Amortization of Acquisition related Intangible | | | | | |
| Assets | 47,625 | | | 9,185 | |
| Tax impact on Amortization of Acquisition related | | | | | |
| Intangible Assets | 10,196 | | | 2,336 | |
| Amortization of Acquisition related Intangible | , | | | | |
| Assets, net of tax (k) | | 37,429 | | | 6,849 |
| Adjusted (Non-GAAP) Net Income ex. | | <u>.</u> | | | |
| Amortization | | 178,067 | | | 141,566 |
| Denominator | | | | | |
| Weighted average shares assuming dilution | | | | | |
| (diluted) | | 113,389 | | | 79,393 |
| djusted (Non-GAAP) EPS ex. Amortization | • | \$ 1.57 | | | \$ 1.78 |

- (a) Represents accelerated depreciation related to a plant relocation in India, as well as a lab closure in Taiwan for 2018.
- (b) Represents adjustments to the contingent consideration payable for PowderPure, and transaction costs related to Fragrance Resources and PowderPure within Selling and administrative expenses.
- (c) For 2019, represents costs related to the integration of the Frutarom acquisition, principally advisory services. For 2018, represents costs related to the integration of the David Michael and Fragrance Resources acquisitions.
- (d) For 2019, represents severance costs related primarily to Scent. For 2018, represents severance costs related to the 2017 Productivity Program and Taiwan lab closure.
- (e) Represents losses related to the FDA mandated recall.
- (f) Represents charges incurred related to enactment of certain U.S. tax legislation changes in December 2017.
- (g) Represents transaction-related costs and expenses related to the acquisition of Frutarom. Amount primarily includes \$7.9 million of amortization for inventory "step-up" costs and \$1.7 million of transaction costs included in Selling and administrative expenses.
- (h) The income tax expense (benefit) on non-GAAP adjustments is computed in accordance with ASC 740 using the same methodology as the GAAP provision of income taxes. Income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for each jurisdiction in which such charges were incurred, except for those items which are non-taxable for which the tax expense (benefit) was calculated at 0%. For fiscal year 2019, these non-GAAP adjustments were not subject to foreign tax credits or valuation allowances, but to the extent that such factors are applicable to any future non-GAAP adjustments we will take such factors into consideration in calculating the tax expense (benefit). For amortization, the tax benefit has been calculated based on the statutory rate on a country by country basis.
- (i) For 2019, net income is reduced by income attributable to noncontrolling interest of \$2.4M.
- (j) The sum of these items does not foot due to rounding.
- (k) Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.